Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2018, Article ID 2734820, 5 pages
Review Article

Establishing the Role of Stereotactic Ablative Body Radiotherapy in Early-Stage Breast Cancer

Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, 610 University Avenue, Toronto, ON, Canada

Correspondence should be addressed to Aisling Barry; ac.nhu.pmr@yrrab.gnilsia

Received 22 August 2017; Accepted 24 December 2017; Published 1 February 2018

Academic Editor: Eleanor E. R. Harris

Copyright © 2018 Aisling Barry and Anthony Fyles. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Stereotactic ablative body radiotherapy (SABR) has a role as definitive therapy in many tumor sites; however, its role in the treatment of breast cancer is less well explored. Currently, SABR has been investigated in the neoadjuvant and adjuvant setting with a number of ongoing feasibility studies. However, its use comes with a number of radiobiological and technical challenges that require further evaluation. We have learned much from other extracranial disease sites such as lung, brain, and spine, where definitive treatment with SABR has shown encouraging outcomes. In women with breast cancer, SABR may eliminate the need for invasive surgery, reducing healthcare costs and hospital stays and providing an additional curative option for early-stage disease. This poses the following question: is there a role for SABR as a definitive therapy in breast cancer?